Thrombophilia markers in acute myocardial infarction of the young

Non

Effect of galantamine on platelet functions in healthy elderly people

Background & objectives: Galantamine, a centrally-acting cholinesterase inhibitor, has been used in the treatment of mild-to-moderate dementia of Alzheimer disease. Increased mortality, mainly due to cardiovascular events, was observed in placebo-controlled trials of galantamine. Several studies have evaluated the efficacy of galantamine in dementia, it is not clear whether it has an effect on platelet function. It is important to clarify this effect, because it may be related to thrombotic tendency or bleeding diathesis. This study was aimed to investigate the effect of galantamine on platelet aggregation in whole blood from healthy, elderly subjects

Effects of Acute Hyperglycemia on Blood Brain Barrier During Pentylenetetrazole-induced Epileptic Seizures

Epileptic seizures are one of the most common neurologic disorder and lead to disruption of Blood-brain Barrier (BBB). In animal experiments, seizure susceptibility has been shown to increase with incremental blood glucose. Moreover, clinical information regarding seizures and parameters of glucose control is lacking. The aim of this study is to examine the effect of acute hyperglycemia on permeability of Blood Brain Barrier (BBB) and the immunoreactivity of Zonula occludens-1 (ZO-1) and Glial Fibrillary Acidic Protein (GFAP) during Pentylenetetrazole (PTZ)-induced epileptic seizures. Experimental rats are divided into four groups. Evans blue was used as BBB tracer; ZO-1 and GFAP were determined by an immunohistochemical method. The BBB permeability of three parts of the brain in acute hyperglycemia+PTZ group compared to PTZ group (p<0.05). Immunoreactivity of ZO-1 decreased in acute hyperglycemic rats (p<0.05). GFAP immunoreactivity also significantly increased in PTZ and acute hyperglycemia+PTZ (p<0.01). This study was conducted to determine if acute hyperglycemia aggravates seizure changes GFAP activation and increases BBB damage during seizures

Regional distribution of glucose-6-phosphate dehydrogenase deficiency in Turkey and evaluation of clinical findings: a multicenter study

Objectives: The single most inherited enzyme deficiency is that of glucose-6-phosphate dehydrogenase (G6PD) with a presence in almost 400 million of theworld’spopulation. Thenumber of reported G6PD mutations is 186. Furthermore, geographical location is a determining factor for the prevalence of G6PD. Therefore, much of the existing epidemiological literature concerning this issue in Turkey has reported data specific to cities and regions. The purpose of this study was to examine G6PD deficiency in a sample of subjects. Outcome measures reported in this study include the clinical factors as sociated with the deficiency, as well as in geographical dispersion across regional locations in Turkey. Methods: This is a retrospective, cross-sectional study. The sample comprised 308 subjects with a G6PD diagnosis. Data collection commenced in January 2011, and was completed by May 2020. Results: In Turkey, the Mediterranean region has the greatest prevalence of G6PD enzyme deficiency. Subjects presenting with this deficiency were also diagnosed with haemolytic anaemia that was attributed to favism. Subsequently, drug and neonatal hyperbilirubinemia-induced haemolysis ensued. Over 90% of subjects diagnosed with a critical G6PD deficiency and recurrent haemolysis were allocated to the Class II variant. Conclusions: The Mediterranean, along with Agean and Marmara regions are where the highest prevalence of G6PD enzyme deficiency are observed. Favism-induced haemolytic anaemia is the most often identified clinical precursor to diagnosis of G6PD deficiency in Turkey. The most common clinical feature after this condition is drug related haemolysis and the onset neonatal hyperbilirubinemia